Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More
Xconomy
JUNE 10, 2016
Plans for new incubators were announced in two different cities. —Two more clinical setbacks decimated the shares of Massachusetts biotechs: Ocular Therapeutix’s (NASDAQ: OCUL ) OTX-DP failed a trial for allergic conjunctivitis , while Catabasis Pharmaceuticals’ (NASDAQ: CATB ) CAT-2054 flunked a study in patients with high cholesterol.
Let's personalize your content